StockData
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Evolus, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)

Close on Oct 19, 2026

Market cap
$485.24M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026During market hours$84.10M––
Q1 FY2026
Ended Mar 31, 2026
May 4, 2026During market hours$73.10M––
Q4 FY2025
Ended Dec 31, 2025
Mar 3, 2026During market hours$90.30M$0.00–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025During market hours$69.00M––
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025During market hours$69.40M$-0.27–
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025During market hours$68.50M$-0.30–
Q4 FY2024
Ended Dec 31, 2024
Mar 4, 2025During market hours$79.00M$-0.11–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours$61.10M––
Q2 FY2024
Ended Jun 30, 2024
Jul 31, 2024During market hours$66.90M$-0.18–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024During market hours$59.30M$-0.22–
Q4 FY2023
Ended Dec 31, 2023
Mar 7, 2024During market hours$61.00M$-0.21–

Company guidance

Outlook given with results on Aug 5, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDA marginsnon-GAAP202813% to 15%New
adjusted gross profit marginnon-GAAPfull-year 202667% to 67.5%Raised
Evolysse ® and Estyme ® injectable HA gels to contribute 10% to 12% of total revenuefull-year 202610% to 12%New
non-GAAP operating expensesnon-GAAPfull-year 2026$212.00M to $216.00MRaised
total net revenuesfull-year 2026$330.00M to $337.00MRaised
total net revenue2028$450.00M to $500.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Evolus filed with the SEC